Loganin improves learning and memory impairments induced by scopolamine in mice.

Loganin is an iridoid glycoside found in the Flos lonicerae, Fruit cornus, and Strychonos nux vomica. We investigated the effect of loganin on learning and memory impairments induced by scopolamine (0.5mg/kg, i.p.), a muscarinic antagonist, using the Y-maze, passive avoidance, and the Morris water maze tests in mice. In the Y-maze test, loganin (40 mg/kg, p.o.) significantly improved the scopolamine-induced memory impairment. In addition, loganin (20 and 40 mg/kg, p.o.) significantly reversed scopolamine-induced impairments measured by the passive avoidance and the Morris water maze tests. A day after the last trial session of the Morris water maze test (probe trial session), loganin (20 and 40 mg/kg) dose-dependently increased the latency time in the target quadrant. Furthermore, loganin significantly inhibited acetylcholinesterase activity in the hippocampus and frontal cortex. Loganin may have anti-amnesic activity that may hold significant therapeutic value in alleviating certain memory impairments observed in Alzheimer's disease.

[1]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  T. Nabeshima,et al.  Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation , 2003, Molecular Psychiatry.

[4]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[5]  M. Giovannini.  The Role of the Extracellular Signal-regulated Kinase Pathway in Memory Encoding , 2006, Reviews in the neurosciences.

[6]  S. Amagaya,et al.  Choleretic actions of iridoid compounds. , 1988, Journal of pharmacobio-dynamics.

[7]  I. Chang.  Liver-protective activities of aucubin derived from traditional oriental medicine. , 1998, Research communications in molecular pathology and pharmacology.

[8]  Ki Yong Lee,et al.  Anti-amnestic activity of E-p-methoxycinnamic acid from Scrophularia buergeriana. , 2003, Brain research. Cognitive brain research.

[9]  H. Fibiger.  Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence , 1991, Trends in Neurosciences.

[10]  S. Kanba,et al.  Altered Expression of COX-2 in Subdivisions of the Hippocampus during Aging and in Alzheimer’s Disease: The Hisayama Study , 2007, Dementia and Geriatric Cognitive Disorders.

[11]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[12]  S. Nam,et al.  Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity , 2009, Journal of Natural Medicines.

[13]  R. Spanagel,et al.  REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview , 2006, Addiction biology.

[14]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[15]  N. Butters,et al.  Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. , 1986, Behavioral and neural biology.

[16]  T. Nabeshima,et al.  Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study , 1998, Neuroscience Letters.

[17]  N. Greig,et al.  Cholinesterases: roles in the brain during health and disease. , 2005, Current Alzheimer research.

[18]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[19]  Ki Yong Lee,et al.  ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice. , 2005, Life sciences.

[20]  C. Winter,et al.  A microdialysis method for the recovery of IL-1β, IL-6 and nerve growth factor from human brain in vivo , 2002, Journal of Neuroscience Methods.

[21]  M. Packard,et al.  The amygdala mediates memory consolidation for an amphetamine conditioned place preference , 2002, Behavioural Brain Research.

[22]  C. C. Lin,et al.  Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis , 2001, Phytotherapy research : PTR.

[23]  T. Tzschentke,et al.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues , 1998, Progress in Neurobiology.

[24]  M. Chan,et al.  Antinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory pain , 2009, Journal of Biomedical Science.

[25]  J. Wehner,et al.  Effects of chronic diisopropylfluorophosphate treatment on spatial learning in mice , 1987, Pharmacology Biochemistry and Behavior.

[26]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[27]  H. Nishino,et al.  Cancer chemopreventive activity of an iridoid glycoside, 8-acetylharpagide, from Ajuga decumbens. , 2000, Cancer letters.

[28]  T. Ahmed,et al.  Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease , 2009, Pharmacology Biochemistry and Behavior.

[29]  Y. Dudai,et al.  Scopolamine induces an increase in muscarinic receptor level in rat hippocampus , 1980, Brain Research.

[30]  J. Cummings,et al.  Neuropsychiatric aspects of Alzheimer's disease , 1996, Neurology.

[31]  A. Chow,et al.  Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta‐amyloid‐induced toxicity in PC12 cells , 2010, Phytotherapy research : PTR.

[32]  H. Ogura,et al.  Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. , 2000, Methods and findings in experimental and clinical pharmacology.

[33]  M. Chan,et al.  Inhibition of smooth muscle contraction by magnolol and honokiol in porcine trachea. , 2003, Planta medica.

[34]  L. Angenot,et al.  Metabolomic analysis of Strychnos nux-vomica, Strychnos icaja and Strychnos ignatii extracts by 1H nuclear magnetic resonance spectrometry and multivariate analysis techniques. , 2004, Phytochemistry.

[35]  H. Okada,et al.  Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice , 2009, Brain Research.

[36]  S. Nakajima,et al.  Differential effects of scopolamine on working and reference memory depend upon level of training , 1992, Pharmacology Biochemistry and Behavior.

[37]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[38]  M. Giovannini,et al.  Cholinesterase inhibitors and memory. , 2010, Chemico-biological interactions.

[39]  P. Gean,et al.  A Role for the PI-3 Kinase Signaling Pathway in Fear Conditioning and Synaptic Plasticity in the Amygdala , 2001, Neuron.

[40]  M. Hasselmo.  The role of acetylcholine in learning and memory , 2006, Current Opinion in Neurobiology.

[41]  A. Blokland.  Acetylcholine: a neurotransmitter for learning and memory? , 1995, Brain Research Reviews.

[42]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[43]  L. Frölich.  The cholinergic pathology in Alzheimer's disease – discrepancies between clinical experience and pathophysiological findings , 2002, Journal of Neural Transmission.

[44]  G. Benzi,et al.  Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? , 1998, European journal of pharmacology.

[45]  V. Mathura,et al.  Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease , 2005, Journal of Neuroinflammation.

[46]  M. Recio,et al.  Structural Considerations on the Iridoids as Anti-Inflammatory Agents , 1994, Planta medica.

[47]  Y. Jang,et al.  Protopine from Corydalis ternata has anticholinesterase and antiamnesic activities. , 1999, Planta Medica.

[48]  M. Mesulam.  The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? , 2004, Learning & memory.

[49]  Jian-Mei Li,et al.  Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  P. Houghton,et al.  Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. , 2004, Planta medica.

[51]  R. Bevins,et al.  Conditioned place preference: what does it add to our preclinical understanding of drug reward? , 2000, Psychopharmacology.

[52]  Elke Geraerts,et al.  A detailed analysis of rats’ spatial memory in a probe trial of a Morris task , 2004, Behavioural Brain Research.

[53]  Shizhong Chen,et al.  Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin , 2005, Acta Pharmacologica Sinica.

[54]  M. Etminan,et al.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies , 2003, BMJ : British Medical Journal.

[55]  Arjan Blokland,et al.  The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies , 2010, Neuroscience & Biobehavioral Reviews.

[56]  J. David Sweatt,et al.  Activation of p42 Mitogen-activated Protein Kinase in Hippocampal Long Term Potentiation* , 1996, The Journal of Biological Chemistry.

[57]  M. Weinstock,et al.  Effect of rivastigmine on scopolamine-induced memory impairment in rats. , 1999, European journal of pharmacology.

[58]  Ping Li,et al.  Determination of five major iridoid glucosides in Flos Lonicerae by high-performance liquid chromatography coupled with evaporative light scattering detection. , 2003, Journal of chromatography. A.

[59]  R. Elble,et al.  POTENTIAL PHARMACOTHERAPY OF ALZHEIMER DISEASE. A COMPARISON OF VARIOUS FORMS OF PHYSOSTIGMINE ADMINISTRATION , 1988, Acta neurologica Scandinavica. Supplementum.

[60]  A. Mutlib,et al.  Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. , 1996, The Journal of pharmacology and experimental therapeutics.

[61]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[62]  J. Arbiser,et al.  Honokiol, a multifunctional antiangiogenic and antitumor agent. , 2009, Antioxidants & redox signaling.

[63]  X. Tang,et al.  Comparative Studies of Huperzine A, E2020, and Tacrine on Behavior and Cholinesterase Activities , 1998, Pharmacology Biochemistry and Behavior.

[64]  J. Ryu,et al.  Protective activities of aucubin against carbon tetrachloride-induced liver damage in mice. , 1983, Drug and chemical toxicology.

[65]  Joseph E. LeDoux,et al.  Emotional memory systems in the brain , 1993, Behavioural Brain Research.

[66]  P. E. Gold,et al.  Competition between Memory Systems: Acetylcholine Release in the Hippocampus Correlates Negatively with Good Performance on an Amygdala-Dependent Task , 2002, The Journal of Neuroscience.

[67]  I. Izquierdo,et al.  LY294002, an inhibitor of phosphoinositide 3-kinase given into rat hippocampus impairs acquisition, consolidation and retrieval of memory for one-trial step-down inhibitory avoidance , 2001, Behavioural pharmacology.

[68]  M. Kopelman,et al.  Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. , 1988, Brain : a journal of neurology.

[69]  Xi Chen,et al.  PI3 kinase signaling is required for retrieval and extinction of contextual memory , 2005, Nature Neuroscience.

[70]  R. Veerhuis,et al.  Costimulatory Effects of Interferon-γ and Interleukin-1β or Tumor Necrosis Factor α on the Synthesis of Aβ1-40 and Aβ1-42 by Human Astrocytes , 2000, Neurobiology of Disease.

[71]  W. B. Stavinoha,et al.  Honokiol, a Putative Anxiolytic Agent Extracted from Magnolia Bark, has no Diazepam‐like Side‐effects in Mice , 1999, The Journal of pharmacy and pharmacology.

[72]  Dong Hyun Kim,et al.  Gomisin A improves scopolamine-induced memory impairment in mice. , 2006, European journal of pharmacology.

[73]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[74]  J. David Sweatt,et al.  The MAPK cascade is required for mammalian associative learning , 1998, Nature Neuroscience.